Anti-CD20 agent has been proposed as a rescue therapy for refractory nephrotic syndrome(NS) on the basis of favorable clinical observations. Yet the long-term effect on maintaining remission or the likelihood of becoming rituximab-dependent is unclear and the information on the safety profile of rituximab is limited. This trial was designed to investigate the safety and efficacy of Rituximab in children with refractory NS.

Further study details as provided by Seoul National University Childrens Hospital:

Primary Outcome Measures:

The remission rate of steroid-resistant nephrotic syndrome patients after rituximab treatment [ Time Frame: within 6 months from the initiation of treatment ] [ Designated as safety issue: No ]

The rate of maintaining remission in steroid-dependent nephrotic syndrome patients [ Time Frame: within 6 months from the initiation of treatment versus placebo control ] [ Designated as safety issue: No ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01716442